BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $58.52 -0.8%
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: -34.0%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Nvidia underperforms peers as report sparks rack delay worries
- Intercontinental Exchange (ICE) PT Lowered to $208 at Raymond James, 'we view the risk/reward as attractive'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
